Other Events ·
On August 27, 2026, the U.S. Food and Drug Administration approved the supplemental Biologics License Application for…
BNTXBioNTech SE
On August 27, 2026, the U.S. Food and Drug Administration approved the supplemental Biologics License Application for the 2026-2027 COVID-19 vaccine formula targeting the XFG variant (COMIRNATY ® XFG). The approval covers use in adults ages 65 years and older, as well as individuals ages 5 through 64 with underlying conditions increasing severe outcome risk. Shipping begins immediately to ensure rapid access for the upcoming season. BioNTech SE is a global biopharmaceutical company pioneering novel immunotherapies for cancer and infectious diseases.